Introduction albumin, 3.3 g/dl (33 g/l ); and phosphorus, 4 mg/dl (1.29 mmol/l ). Twenty four hour urinary calcium excreHigh dose magnesium therapy, which causes profound tion was 300 mg. A day later plasma PTH (intact PTH hypermagnesaemia, is an established therapy for immunoassay kit, Nichols Institute Diagnostics, San eclampsia and premature labour. Usually the hyperJuan Capistrano, CA, USA) level was <8.5 pg/ml magnesaemia is tolerated well. More than two decades (normal range 10-65 pg/ml ). Intravenous calcium was ago hypocalcaemia was described in two obstetric given but due to continued labour and symptomatic patients receiving magnesium [1, 2] .
hypocalcaemia, magnesium therapy was stopped Cholst et al.
[3] studied a group of seven pregnant ( Figure 1 ). The symptoms of hypocalcaemia resolved women and showed that hypermagnesaemia-induced with the rise of serum calcium and the decline of serum hypocalcaemia was associated with transient hypoparamagnesium. Plasma PTH level increased to 26 pg/ml on thyroidism. Of note is the lack of symptoms in the day 3. She gave birth on the 25th week of her pregnancy. women who had hypocalcaemia. We present two patients who had magnesium tocolytic therapy, and during hypermagnesaemia developed prolonged symptomatic Case 2 hypocalcemia and undetectable PTH concentrations. We propose the involvement of the calcium-sensing receptor A 27-year-old woman on the 19th week of her pregin hypermagnesaemia-induced hypocalcaemia.
nancy was admitted due to suspected twin to twin transfusion. During her stay in the ward premature labour occurred. As she did not respond to b-adre-
Case 1
nergic agonists and indomethacin, she was started on intravenous magnesium sulfate (a loading dose of 5 g A 28-year-old woman after in vitro fertilization procedand a maintenance dose of 2 g/h). On the second day ure was pregnant with twins. On the 24th week of a routine blood chemistry analysis showed a calcium pregnancy she had vaginal bleeding and premature level of 6.5 mg/dl (1.62 mmol/l ). On the third day of labour. She was started on oral b-adrenergic agonists magnesium treatment she complained of hoarseness, and 4 days later intravenous magnesium sulfate was muscle spasms, and was found to have tetany. Physical administered. Twelve hours after a loading dose of 5 g examination showed a positive Chvostek sign and of magnesium sulfate and a maintenance dose of 2 g/h, tendon hyperreflexia. Initial laboratory tests on admisshe complained of diplopia, general malaise, and paression including renal function were within normal limits. thesia especially over the face and extremities. On When symptoms occurred laboratory results showed examination a prominent Chvostek sign with marked the following serum biochemical values: magnesium, hyperreflexia were noticed. There were no signs of 6.1 mg/dl (2.51 mmol/l ); calcium, 6.3 mg/dl toxaemia. EKG showed a prolonged Q-T interval.
(1.57 mmol/l ); ionized calcium, 0.84 mmol/l; albumin, Initial laboratory tests done on admission were within 3.4 g/dl (34 g/l ); and phosphorus, 3 mg/dl (1 mmol/l ). normal limits. When symptoms appeared, laboratory Plasma PTH level was <8.5 pg/ml. Intravenous and results showed the following serum concentrations:
oral calcium were given with concomitant intravenous magnesium, 6.5 mg/dl (2.67 mmol/l ); total calcium, magnesium sulfate for another 8 days. She was intermittently symptomatic due to on going hypocalcaemia.
Symptomatic hypocalcaemia during magnesium therapy hypocalcaemia and hypermagnesaemia ( Figure 2 ). induced by hypermagnesaemia was of a 20-year-old PTH levels were below detectable limits (<8.5 pg/ml ) woman who developed toxaemia and was treated by on three different days during magnesium therapy, and magnesium sulfate [1]. Serum magnesium concentraafter discharge, rose to 10 pg/ml. Nifedipine and indo-tion was 10 mg/dl (4.11 mmol/l ) while serum total methacin were started, with resolution of the premature calcium level was 6.7 mg/dl (1.67 mmol/l ), with serum contractions. She was discharged and resumed her albumin of 2.3 g/dl (23 g/l ). . We have found only two published case reports of was that of a 29-year-old woman, who developed symptomatic patients. The reported cases were hypocalcaemia (4.9 mg/dl, 1.22 mmol/l )) 2 days after pregnant women who also had other conditions which magnesium therapy was stopped, while magnesium might have contributed to the hypocalcaemia.
The first observation of symptomatic hypocalcaemia levels were within normal range. Plasma PTH level H
was achieved by Brown and colleagues who cloned a Our two patients were different from the above calcium-sensing receptor from bovine and human paracases. They both developed hypocalcaemia while magthyroid glands [9, 10] . It has been shown that the receptor nesium was administered. There was no other condition which has a high affinity for calcium is not selective for or cause exposing them to hypocalcaemia. In both, calcium. Functional expression of the calcium-sensing hypocalcaemia appeared within hours after starting receptor cRNA in Xenopus Laevis oocytes [9,11] showed magnesium administration. Symptoms of hypocalcaethat, while EC 50 of Ca+2 was 3 mM, Mg+2, evoked large mia appeared within 1-2 days later. This was accominward currents with EC 50 of 10 mM [9] . This concentrapanied by a decrease in plasma intact PTH tion is in the same order of magnitude as that observed concentration, which in the first patient lasted for at during tocolytic magnesium therapy. Therefore, we proleast 24 h, and in the second patient persisted for 8 pose that hypermagnesaemia could act on the calciumdays despite ongoing hypocalcaemia.
sensing receptor in parathyroid tissue, decrease PTH Cholst et al.
[3] studied prospectively seven pregnant secretion and thereby participate in the genesis of hypowomen who were given magnesium tocolytic therapy,
calcaemia. An additional action on the calcium-sensing consisting of a loading dose followed by a maintenance receptor at the renal level is however also possible. dose over 3 h. Mean serum magnesium increased to Further studies are needed to determine whether a 6.1 mg/dl (2.51 mmol/l ), and mean serum total calmodified parathyroid status during pregnancy is a cium decreased from 8.6 (2.14 mmol/l ) to 7.6 mg/dl prerequisite for the observation that only some women (1.89 mmol/l ), without symptoms. Plasma PTH con-develop hypermagnesaemia-induced hypocalcaemia. centration, measured using an antibody directed against PTH C-terminus, decreased from 13.1 to
